These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison. Pinkawa M; Piroth MD; Holy R; Fischedick K; Klotz J; Székely-Orbán D; Eble MJ Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):23-8. PubMed ID: 20832182 [TBL] [Abstract][Full Text] [Related]
28. Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Stenmark MH; Conlon AS; Johnson S; Daignault S; Litzenberg D; Marsh R; Ritter T; Vance S; Kazzi N; Feng FY; Sandler H; Sanda MG; Hamstra DA Radiother Oncol; 2014 Feb; 110(2):291-7. PubMed ID: 24507766 [TBL] [Abstract][Full Text] [Related]
29. Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study. Pinkawa M; Holy R; Piroth MD; Fischedick K; Schaar S; Székely-Orbán D; Eble MJ Radiat Oncol; 2010 Apr; 5():27. PubMed ID: 20377874 [TBL] [Abstract][Full Text] [Related]
30. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Kupelian PA; Reddy CA; Klein EA; Willoughby TR Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):988-93. PubMed ID: 11704322 [TBL] [Abstract][Full Text] [Related]
31. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy. Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270 [TBL] [Abstract][Full Text] [Related]
32. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103. Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706 [TBL] [Abstract][Full Text] [Related]
33. Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer. Zhang Y; Li P; Yu Q; Wu S; Chen X; Zhang Q; Fu S Radiat Oncol; 2019 Jun; 14(1):94. PubMed ID: 31164172 [TBL] [Abstract][Full Text] [Related]
34. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. Shaikh T; Li T; Handorf EA; Johnson ME; Wang LS; Hallman MA; Greenberg RE; Price RA; Uzzo RG; Ma C; Chen D; Geynisman DM; Pollack A; Horwitz EM Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):722-731. PubMed ID: 28244407 [TBL] [Abstract][Full Text] [Related]
35. Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications. Hutchinson RC; Sundaram V; Folkert M; Lotan Y Urol Oncol; 2016 Jul; 34(7):291.e19-26. PubMed ID: 27038698 [TBL] [Abstract][Full Text] [Related]
36. Rectal spacing, prostate coverage, and periprocedural outcomes after hydrogel spacer injection during low-dose-rate brachytherapy implantation. Kahn J; Dahman B; McLaughlin C; Kapoor P; Kapoor R; Harris E; Sharma M; Schutzer M; Moghanaki D Brachytherapy; 2020; 19(2):228-233. PubMed ID: 32085930 [TBL] [Abstract][Full Text] [Related]
37. One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer. Poon DMC; Yuan J; Wong OL; Yang B; Tse MY; Lau KK; Chiu ST; Chiu PK; Ng CF; Chui KL; Kwong YM; Ma WK; Cheung KY; Chiu G; Yu SK World J Urol; 2024 Feb; 42(1):97. PubMed ID: 38393414 [TBL] [Abstract][Full Text] [Related]
38. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial. Iarrobino NA; Gill B; Sutera PA; Kalash R; D' Ambrosio D; Heron DE Am J Clin Oncol; 2019 Nov; 42(11):856-861. PubMed ID: 31584457 [TBL] [Abstract][Full Text] [Related]
39. Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy. Wilder RB; Barme GA; Gilbert RF; Holevas RE; Kobashi LI; Reed RR; Solomon RS; Walter NL; Chittenden L; Mesa AV; Agustin JK; Lizarde J; Macedo JC; Ravera J; Tokita KM Brachytherapy; 2011; 10(1):44-50. PubMed ID: 20591748 [TBL] [Abstract][Full Text] [Related]
40. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes. Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]